Open Access
Review
Table 3
Summary of metabolomics studies conducted in AD human samples.
| Sample Size | Sample Source | Platform | Findings | Ref. |
|---|---|---|---|---|
| AD(n = 22) CN(n = 18) |
Serum | DIMS | ↓PUFA-PCs; ↑SFA-PCs |
(Gonzalez-Dominguez et al., 2012) |
| AD(n = 22) CN(n = 18) |
Serum | DIMS | ↓PUFA-PLs, valine, glutamine, N-acetyl-glutamine, glutamate, histidine, arginine, dopamine, carnitine, creatine; ↑SFA-PLs, free fatty acids, eicosanoids, triglycerides, choline, glycerophosphocholine, glucose |
(Gonzalez-Dominguez et al., 2014e) |
| AD(n = 22) CN(n = 18) |
Serum | DIMS | ↓PUFA-PLs, oleamide, histidine, arginine, imidazole, taurine, guanidine, putrescine; ↑eicosanoids, diglycerides, kynurenine |
(Gonzalez-Dominguez et al., 2014c) |
| AD(n = 19) CN(n = 17) |
Serum | DIMS | ↓PUFA-PLs, LPLs, plasmalogens; ↑SFA-PLs |
(Gonzalez-Dominguez et al., 2014b) |
| AD(n = 30) CN(n = 30) |
Serum | DIMS | ↓Fatty acid amides, urea, creatine, malate, taurine, dopamine, serotonin; ↑ceramides, diglycerides, free fatty acids, alanine, picolinic acid |
(Gonzalez-Dominguez et al., 2015a) |
| AD(n = 26) CN(n = 26) |
Plasma | DIMS | ↓Long-chain sphingomyelins; ↑ceramides |
(Han XL et al., 2011) |
| AD(n = 90) MCI(n = 77) CN(n = 51) |
Serum | DIMS | ↓Plasmalogens; ↑diglycerides |
(Wood et al., 2016) |
| AD(n = 43) MCI(n = 33) CN(n = 35) |
Plasma | DIMS | ↓Phosphatidylcholines; ↑lyso-phosphatidylcholines |
(Klavins et al., 2015) |
| AD(n = 23) CN(n = 21) |
Serum | GC-MS | ↓Valine, urea, aspartate, pyroglutamate, glutamine, phenylalanine, asparagine, ornithine, pipecolate, histidine, tyrosine, palmitic acid, urate, tryptophan, stearic acid, cysteine; ↑lactate, α-ketoglutarate, isocitrate, glucose, oleic acid, adenosine, cholesterol |
(Gonzalez-Dominguez et al., 2015b) |
| AD(n = 37 CN(n = 46) |
Serum | GC-MS | ↑Glutamate | (Orešič et al., 2018) |
| AD(n = 10) MCI(n = 10) CN(n = 10) |
Plasma | RP-MS | ↓Lysophospholipid (18:1) | (Sato et al., 2010) |
| AD(n = 10) CN(n = 10) |
Plasma | RP-MS | ↓Demosterol | (Sato et al., 2012) |
| AD(n = 16) MCI(n = 12) CN(n = 10) |
Plasma | RP-MS | ↑1-(9E-hexadecenoyl)-sn-glycero-3-phosphocholine, d-glucosaminide, glycocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid | (Greenberg et al., 2009) |
| AD(n = 20) CN(n = 20) |
Plasma | RP-MS | ↓Lysophosphatidylcholines, tryptophan, phytosphingosine, dihydrosphingosine, hexadecasphinganine | (Li et al., 2010a) |
| AD(n = 36) MCI(n = 48) CN(n = 40) |
Plasma | RP-MS | ↓Long chain cholesteryl esters | (Proitsi et al., 2015) |
| AD(n = 205) CN(n = 207) |
Plasma | RP-MS | ↓Phosphatidylcholines ↑Ceramide |
(Kim et al., 2016) |
| AD(n = 52) MCI(n = 62) CN(n = 59) |
Plasma | RP-MS | ↓Phosphatidylcholines | (Whiley et al., 2014) |
| AD/MCI(n = 35) Converters(n = 18) CN(n = 53) |
Plasma | RP-MS | ↓Phosphatidylcholines, lyso-phospholipids, serotonin, phenylalanine, proline, lysine, taurine, acyl-carnitines, malate; ↑glycoursodeoxycholic acid, proline-asparagine |
(Mapstone et al., 2014) |
| AD(n = 75) MCI(n = 17) CN(n = 45) |
Serum | RP-MS | ↓PUFA-PLs, PUFA-SMs, sulfatides, monoglycerides, oleamide, histidine pregnenolone sulfate; ↑SFA-PLs, SFA-SMs, ceramides, acyl-carnitines, phenyl-acetyl-glutamine |
(Raúl et al., 2016) |
| AD(n = 148) CN(n = 152) |
Plasma | RP-MS | ↓Cholesteryl esters, triglycerides; ↑phosphatidylcholine |
(Proitsi et al., 2017) |
| AD(n = 175) MCI(n = 356) CN(n = 189) |
Serum | RP-MS | ↓Acyl-carnitines, phosphatidylcholines, sphingomyelins; ↑valine, α-aminoadipic acid |
(Toledo et al., 2017) |
| AD(n = 660) MCI(n = 583) |
Serum | RP-MS | ↑Sphinganine-1-phosphate, 7-ketocholesterol, 3-methoxytyrosine, deoxyribose-5-phosphate, p-phenyllactic acid, lyso-phosphatidylcholine; ↓phenylalanine, ornithine, glutamate |
(Liang et al., 2016b) |
| AD(n = 46) CN(n = 37) |
Serum | RP-MS | ↓1-methylinosine, 16-bromo-9-hexadecenoic acid, lysophosphatidylcholines, dihydrosphingosine, N-acetyl-glutamine, 1α, 25-dihydroxy-2α-(3-hydroxypropoxy) vitamin D3; ↑palmitic amide, monoiodothyronine, antrimethyltridecanoic acid, PGE2α dimethyl amine, (6R)-vitamin D3 6, 19- (4-phenyl-1, 2, 4-triazoline-3, 5-dione) |
(Cui et al., 2014) |
| AD_MCI(n = 19) MCI(n = 16) CN(n = 37) |
Plasma | HILIC-MS | ↓4-amino-butanal, γ-aminobutyric acid, ornithine, N-acetyl-putrescine; ↑creatine, arginine, methylthioadenosine, N-acetyl-spermidine, N-diacetyl-spermine, putrescine, spermidine, spermine |
(Graham et al., 2015) |
| AD(n = 42) MCI(n = 14) CN(n = 37) |
Serum | CE-MS | ↓Creatine, asparagine, methionine, histidine, carnitine, N-acetyl-spermidine, valeryl-carnitine; ↑choline, creatinine, dimethylarginine, homocysteinyl-cysteine, acyl-carnitines, peptides |
(Gonzalez-Dominguez et al., 2014a) |
| AD(n = 47) MCI(n = 143) CN(n = 46) |
Serum | RP-MS/ GC-MS |
Baseline: ↓plasmalogens, phosphatidylcholines, sphingomyelins, sterols; ↑histamine Progression: ↑2, 4-dihydroxybutanoic acid |
(Orešič et al., 2011) |
| AD(n = 57) MCI(n = 58) CN(n = 57) |
Plasma | RP-MS/ GC-MS |
↓Fatty acids, dimethylglycine, glutamate, uridine, glyceraldehyde, butanedioic acid, 2-butenedioic acid, 5-oxoproline, taurine, hypotaurine, malate; ↑glutamine, 2-aminoadipic acid, proline, cysteine, cytidine, thymine, hypoxanthine, carbohydrates, citrate |
(Wang G et al., 2014) |
| AD(n = 30) MCI(n = 30) CN(n = 30) |
Plasma | RP-MS/ HILIC-MS |
↓Sphingomyelins | (Armirotti et al., 2014) |
| AD(n = 15) MCI(n = 15) CN(n = 15) |
Plasma | RP-MS/ HILIC-MS |
Changes in more than 150 metabolites (amino acids, energy-related metabolites, lipids, neurotransmitters) | (Trushina et al., 2013b) |
| AD(n = 3) FTD(n = 4) LBD(n = 3) CN(n = 9) |
Serum | CE-MS | ↑β-alanine, creatinine, hydroxyproline, glutamine, isocitrate, cytidine | (Tsuruoka et al., 2013) |
| AD(n = 12) CN(n = 5) |
Whole brain | MRS | ↓N-acetyl-aspartate, γ-aminobutyric acid; ↑ glutamate |
(Klunk et al., 1992) |
| AD(n = 13) CN(n = 4) |
Temporoparietal cortex | MRS | ↓N-acetyl-aspartate, creatine, γ-aminobutyric acid | (Mohanakrishnan et al., 1995) |
| AD(n = 13) CN(n = 4) |
Hippocampus, cerebellum | MRS | ↓N-acetyl-aspartate, γ-aminobutyric acid | (Mohanakrishnan et al., 1997) |
| AD(n = 8) ALS(n = 11) |
Frontal cortex | NMR | ↑Alanine, acetate, glutamate, glutamine; ↓lactate, creatine |
(Botosoa et al., 2012) |
| AD(n = 15) CN(n = 15) |
Neocortex | NMR | ↑Alanine, taurine | (Graham et al., 2014) |
| AD(n = 24) CN(n = 6) |
Superior frontal cortex, superior temporal cortex, inferior parietal cortex, cerebellum | DIMS | ↓Plasmalogens | (Han et al., 2001) |
| AD(n = 17) CN(n = 5) |
Middle frontal gyrus, superior temporal gyrus, inferior parietal lobule, hippocampus, subiculum, entorhinal cortex | DIMS | ↓Sulfatides; ↑ceramides |
(Han et al., 2002) |
| AD(n = 6) CN(n = 8) |
Superior frontal gyrus | DIMS | ↓Sulfatides | (Cheng et al., 2013) |
| AD(n = 34) MCI(n = 19) CN(n = 28) |
Frontal cortex grey matter, frontal cortex white matter | DIMS | ↓Plasmalogens, phosphatidylethanolamines, docosahexaenoic acid, phosphatidylethanolamines, sulfatides; ↑monoglycerides, diglycerides ; ↑monoglycerides, diglycerides, VLCFA 26:0 |
(Wood et al., 2015) |
| AD(n = 9) CN(n = 9) |
Hippocampus, entorhinal cortex, middle-temporal gyrus, sensory cortex, motor cortex, cingulate gyrus, cerebellum | GC-MS | Changes in 55 metabolites, including energy related metabolites (glucose metabolism, TCA), amino acids, nucleosides, and others | (Xu et al., 2016) |
| AD(n = 10) CN(n = 10) |
Frontal lobe, parietal lobe, occipital lobe | RP-MS | ↑Spermidine, spermine, N-acetyl-spermidine, N-acetyl-spermine, putrescine | (Inoue et al., 2013) |
| ADI–II(n = 7) ADIII–IV(n = 4) ADV–VI(n = 5) CN(n = 4) |
Entorhinal cortex | RP-MS | ↓dGMP, glycine, xanthosine, inosine diphosphate, deoxyguanosine; ↑guanine |
(Ansoleaga et al., 2015) |
| AD(n = 15) CN(n = 15) |
Neocortex | HILIC-MS | Seventy-six unidentified discriminant signals | (Graham et al., 2013a) |
| AD(n = 21) CN(n = 19) |
Frontal cortex | RP-MS/ HILIC-MS |
Alterations in the metabolism of phospholipids and six metabolic pathways of the central metabolism: Alanine, Aspartate, and Glutamate Metabolism; Arginine and Proline Metabolism; Cysteine and Methionine Metabolism; Glycine, Serine, and Threonine Metabolism; Purine Metabolism; Pantothenate and CoA Biosynthesis | (Paglia et al., 2016) |
| AD(n = 14) asyAD(n = 15) CN(n = 14) |
Middle frontal gyrus Inferior temporal gyrus Cerebellum |
RP-MS | ↓Glucose | (An et al., 2017) |
| AD(n = 14) asyAD(n = 15) CN(n = 14) |
Middle frontal gyrus Inferior temporal Gyrus Cerebellum |
GC-MS | ↑Cholestenol, docosahexaenoic acid, carbamic acid, hexanedioic acid, ascorbate, gluconic acid, cysteine, L-DOPA, allantoin, coumaric acid, adenine, deoxyflurouridine, arginine, GABA; ↓cholesterol, linoleic acid, methyl-heptadecadiynoic acid, oleic acid, palmitic acid, dimethylglycine, guanidobutanoate, aminobutanal, aspartate, fumaric acid, linolenic acid, indoleacetic acid, eicosapentaenoic acid, hypoxanthine, oxoarginine, methyl-stearate, octadecanal |
(Snowden et al., 2017) |
| AD(n = 15) CN(n = 15) |
Post-mortem CSF | LCECA | ↓Norepinephrine, α-tocopherols, 3-methoxytyramine, ascorbate; ↑5-hydroxytryptophan, methoxy-hydroxyphenyl glycol |
(Kaddurah-Daouk et al., 2011) |
| AD(n = 34) MCI(n = 19) CN(n = 28) |
CSF | MS | CSF: ↓docosahexaenoic | (Wood et al., 2015) |
| AD(n = 20) CN(n = 27) |
CSF | NMR | Specific resonances in AD (unidentified) | (Kork et al., 2009) |
| AD(n = 10) CN(n = 34) |
CSF | NMR | ↑Creatinine | (Jukarainen et al., 2008) |
| AD(n = 76) early_AD(n = 26) MCI(n = 33) CN(n = 45) |
CSF | NMR | Phenylalanine, glutamate, lactate, acetate, α-hydroxyisovalerate, α-hydroxybutyrate | (Laakso et al., 2015) |
| AD(n = 50) CN(n = 50) |
CSF | DIMS | ↑Sphingomyelins, phosphatidylcholines | (Koal et al., 2015) |
| AD(n = 17) CN(n = 17) |
CSF | RP-MS | Fifty-three unidentified discriminant signals | (Myint et al., 2009) |
| AD(n = 40) MCI(n = 36) CN(n = 38) |
CSF | RP-MS | ↑Methionine, 5-hydroxyindoleacetic acid, vanillylmandelic acid, xanthosine, glutathione, hypoxanthine | (Kaddurah-Daouk et al., 2013) |
| AD(n = 23) AD_MCI(n = 9) sMCI(n = 22) CN(n = 19) |
CSF | CE-MS | ↓Arginine, suberylglycine, carnitine, histidine; ↑choline, valine, tripeptide, dimethylarginine, creatine, serine |
(Ibanez et al., 2012) |
| AD(n = 79) CN(n = 51) |
CSF | RP-MS/ GC-MS |
↓Uridine; ↑cysteine, tyrosine, phenylalanine, methionine, serine, pyruvate, taurine, creatinine, cortisol, dopamine |
(Czech et al., 2012) |
| AD(n = 40) CN(n = 38) |
CSF | RP-MS/ GC-MS |
Two unidentified discriminant signals | (Motsinger-Reif et al., 2013) |
| AD(n = 21), cMCI(n = 12) sMCI(n = 21) CN(n = 21) |
CSF | RP-MS/ HILIC-MS |
Changes in levels of uracil, xanthine, uridine, tyrosyl-serine, methylsalsolinol, nonanoylglycine, dopamine-quinone, caproic acid, vanylglycol, histidine, pipecolic acid, hydroxyphophinyl-piruvate, creatinine, taurine, C16-sphingosine-1-phosphate, tryptophan, 5′-methylthioadenosine | (Ibanez et al., 2013) |
| AD(n = 15) MCI(n = 15) CN(n = 15) |
CSF | RP-MS/ HILIC-MS |
Changes in more than 150 metabolites (amino acids, energy-related metabolites, lipids, neurotransmitters) | (Trushina et al., 2013a) |
| AD(n = 256) CN(n = 218) |
Saliva | RP-MS | ↓Inosine, 3-dehydrocarnitine, hypoxanthine; ↑sphinganine-1-phosphate, ornithine, p-phenyllactic acid |
(Liang et al., 2015) |
| AD(n = 660) MCI(n = 583) |
Saliva | RP-MS | ↓Inosine, 3-dehydrocarnitine, hypoxanthine; ↑cytidine, sphinganine-1-phosphate, ornithine, p-phenyllactic acid, pyroglutamate, glutamate, tryptophan |
(Liang et al., 2016a) |
| MCI(n = 20) CN(n = 20) |
Saliva | RP-MS | ↓Taurine, peptides, 1, 8-diazacyclotetradecane-2, 9-dione, 4-(hydroxylamino)-N, N-dimethylaniline; ↑2-amino-heptanoic acid/l-alanine-n-butyl ester/N-methyl-isoleucine |
(Zheng et al., 2012) |
| AD(n = 3) FTD(n = 4) LBD(n = 3) CN(n = 9) |
Saliva | CE-MS | ↓Arginine, tyrosine | (Tsuruoka et al., 2013) |
| AD(n = 46) CN(n = 37) |
Urine | RP-MS | ↓Acetyl-carnitine, estra-1, 3, 5(10), 7-tetraene-3, 17α-diol, p-cresol glucuronide, etiocholanolone glucuronide ; ↑N-acryloylglycine, argininosuccinic acid, dethiobiotin, isobutyryl-l-carnitine, 2-hydroxy-N-(2-hydroxyethyl)-N, N-dimethyl-1-dodecanaminium, l-aspartyl-4-phosphate, l-glutamine, 5-l-glutamylglycine, azelaic acid, aminopterin, cytidine |
(Cui et al., 2014) |
| AD(n = 31) MCI(n = 15) CN(n = 36) |
Hair | GC-MS | ↑7β-hydroxycholesterol | (Son et al., 2016) |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.